News

Investor's Business Daily on MSN2d
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal?
Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...
Exact Sciences signs exclusive deal with biotech firm Freenome
Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...
STAT3d
Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test
Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...
Pharmabiz1d
Freenome enters exclusive license agreement with Exact Sciences to commercialize Freenome’s blood-based screening test for colorectal cancer
Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...
Exact Sciences plans layoffs as it acquires rights to cancer screening blood test
The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...
Medical Marketing & Media1d
Rx Rundown: Pfizer, SERB Pharmaceuticals, Novo Nordisk and more
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Exact Sciences Announces Second Quarter 2025 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
STAT2d
Pharmalittle: We’re reading about mRNA cancer vaccines, Lilly’s disappointing obesity pill data, and more
Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...
Exact Sciences shares plunge despite earnings beat
Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...